Viracta Therapeutics

Viracta Therapeutics is a clinical-stage drug development company that specializes in viral activation therapy to target cancers linked to the Epstein-Barr Virus and other virus-associated diseases. The company's primary drug candidate, nanatinostat, is a selective small molecule inhibitor used in combination with the antiviral valganciclovir. This combination is being investigated for the treatment of various malignancies, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T-cell lymphoma. Viracta is conducting multiple clinical trials to evaluate the efficacy of this treatment, particularly for relapsed or refractory Epstein-Barr virus-positive lymphoma. Founded in 2007 and based in Cardiff, California, the company was previously known as HemaQuest Pharmaceuticals and rebranded in 2015. Viracta Therapeutics aims to provide innovative solutions for serious diseases associated with viral infections.